Travere Therapeutics (TVTX) Stock Forecast & Price Target

Travere Therapeutics is viewed favorably because FILSPARI is demonstrating strong commercial momentum, with 2Q26 revenue of $141.1M and 2,012 new patient start forms, while management has also indicated broad FSGS adoption and faster conversion from start forms to patients on therapy than during the initial IgAN launch. The company’s balance sheet appears supportive, with $489.2M in cash, cash equivalents and marketable securities at the end of 1Q 2026 expected to fund operations into the future, and the leadership transition is presented as non-disruptive since Eric Dube’s departure is tied to health and family rather than business issues. Fundamentally, the positive outlook is reinforced by a late-stage rare-disease pipeline anchored by sparsentan in FSGS and IgAN and pegtibatinase in HCU, alongside continued expectations for strong execution as FSGS growth progresses and IgAN growth continues.

Travere Therapeutics is fundamentally challenged by its heavy dependence on Filspari, with the FSGS franchise described as the main driver of mid- to long-term sales, making the investment case vulnerable if adoption, reimbursement, or competition undercut that single asset despite the newly extended exclusivity into October 2037. Even with an rNPV framework supporting $5.4 billion and net cash of $264 million, the valuation still hinges on assumptions that can deteriorate quickly if clinical readouts are inconclusive or if the company fails to secure adequate funding to advance its pipeline. The broader pipeline remains too early and too narrow to offset concentration risk, as civorebrutinib is only included in PMN and pegtibatinase has yet to prove it can materially diversify the story beyond a Filspari-centric business.